Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Lloyds branch closures and UK 'challenges' factor in 2% revenue drop

The sale or closure of around 200 Lloydspharmacies over the past year has contributed to a 2% drop in revenue for the three months to September, according to McKesson.

The company announced that revenue in its European pharmaceutical solutions division – which includes Lloydspharmacy and wholesaler AAH – was $6.6 billion (£5.2bn) for July-September 2018, a 2% drop compared with the same period last year.

It follows a 9% year-on-year rise in revenue for the division for April-June, which the company attributed to its “restructuring programme”.

"Reduction in owned pharmacies"

In October 2017, Lloydspharmacy announced it would cease trading in around 190 “commercially unviable” pharmacies in England, “through a combination of store closures and divestments”. C+D has since identified 78 Lloydspharmacies that have closed, and 104 that have been sold.

The revenue drop in the three months to September 2018 was “primarily driven by the previously disclosed reduction in owned retail pharmacies and a challenging operating environment in the UK”, as well as “increased competition in France”, the company said in its latest financial report, published last week (October 25).

Speaking to journalists after the latest results were published, McKesson executive vice president and chief financial officer Britt Vitalone said the division’s operating profit after taxes was down 40% to $53m (£41.7m) for July-September.

This was “driven primarily” by the additional 17p-per-item category M clawback in July, “market conditions in our UK business, and increased competition in the French wholesale market”, he said.

“Facing a challenging market in the UK due to reimbursement cuts and declining prescription volumes, we took action last year to rationalise our store footprint and streamline our back office operations,” chief executive and chairman John Hammergren explained in the call.

“As these trends evolved in the UK, we continued to evaluate our footprint and cost structure, and our UK colleagues remain committed to stabilising the business and repositioning it for long-term profitability. All led by a newly appointed president [see below] with more than a decade of industry experience,” he added.

He admitted that the category M clawbacks “were in excess of historical levels and greater than we had planned for in our fiscal 2019 guide”.

“Difficulty predicting how cuts would affect us”

Also on the conference call, McKesson president and chief operating officer Brian Tyler said the company “continues to be in very active dialogue with regulators in the UK to champion” the sector.

“Community pharmacy plays an important role in the overall population health of the communities that they serve. And so we continue to evolve our model in that direction,” he explained.

“Clearly, the reimbursement landscape has been a challenging one for us, not just in the magnitude of the cuts we absorb, but in the difficulty of predicting when and how those cuts have hit us.”

Commenting on last week's funding announcement, Mr Tyler said he was “encouraged” that funding for pharmacies in England “will remain flat for the coming year, where the original intent had been to impose some more decline”.

“We view that as certainly incrementally positive news for us,” he said.

How have your earnings changed over the past year?

Related Content

Topics

         
Pharmacy Manager
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel